Novel PET Tracer Development and Positron Emission Tomography Tracer Solutions

Our full-service model covers every stage of new tracer development — from preclinical in vivo studies to first-in-human trials. Services include radiotracer synthesis, regulatory strategy, imaging protocol design, data acquisition, and quantitative analysis for both research and therapeutic applications.

Whether in mouse models or human subjects, we apply high sensitivity, noninvasive imaging methods to measure specificity, uptake, and target engagement. This includes advanced central nervous system imaging where PET tracersdirectly inform diagnosis and treatment decisions.

Novel PET tracer development requires precision — and it’s where our expertise is focused. We bring deep knowledge of tracer specificity, safety, and operational efficiency to each project.

Our team can help you synthesize and evaluate your tracer, manage short half-life constraints, and design studies to assess in vivo performance before clinical deployment. We work with radiotracers targeting receptors, enzymes, and pathological proteins, including applications in Alzheimer’s disease and other neurodegenerative disorders. Our collaborations connect with scientific communities such as the Society of Nuclear Medicine (SNMMI) and the Journal of Nuclear Medicine to ensure your science is communicated to the right audiences.

• Regulatory guidance for exploratory IND/CTA submissions in nuclear medic
• Protocol design tailored to tracer kinetics (fast-clearing
• Quantitative analysis of early-phase data, including SUVs, compartmental modeling, a
• Scientific collaboration with pharma and academic partners, supporting study design, strategy, and publication in the Journal.

Short-lived radiolabeled compounds such as carbon-11 or oxygen-15 require expert handling. Our integrated radiochemistry and imaging workflows enable rapid synthesis, seamless transfer, and precise scanning — ideal for preclinical and early-phase human trials with fast-clearing brain tracers. This ensures high-quality, reproducible molecular imaging data and accurate measurement of brain uptake with high sensitivity.

ZRO Imaging is the trusted partner for PET imaging trials, combining speed, quality, and deep expertise in nuclear medicine and molecular imaging. We deliver precise in vivo data for therapeutic development and understand the nuances of radiolabeled tracers — from receptor binding and brain uptake to clearance rates and synthesis workflows. Sponsors choose ZRO for reliability, expertise, and a collaborative approach.